Kyowa Kirin Plans $530 Million Investment for New Biologics Manufacturing Plant in North Carolina
Introduction
Kyowa Kirin, Inc., a global specialty pharmaceutical company headquartered in Japan, has announced plans to invest up to $530 million in building a new manufacturing facility in Sanford, North Carolina.
Features
This state-of-the-art facility, spanning 171,700 square feet with two reactors, aims to accelerate the development and production of biologic therapies for rare and serious diseases.
It will also support economic growth in Sanford by creating over 100 high-paying jobs.
Backed by performance-based incentives totaling $10 million over 12 years from state and local authorities.
This investment is forecasted to boost North Carolina's economy by approximately $1.05 billion
The facility is expected to create over 100 new local jobs with an average salary of $91,496.
Construction is set to begin in the second half of 2024, with full operational status expected by 2027.
Located at Helix Innovation Park at The Brickyard, the site allows for future expansion as Kyowa Kirin's pipeline grows, enhancing its global manufacturing capabilities.
Specification
Name New Biologics Manufacturing facility
Type New Construction
Year 2027
